Tolerance of Scottish National Blood Transfusion Service Intravenous Immunoglobulin in Patients with Primary Hypogammaglobulinaemia: Report of 1235 Infusions
Restricted accessResearch articleFirst published online August, 1988
Tolerance of Scottish National Blood Transfusion Service Intravenous Immunoglobulin in Patients with Primary Hypogammaglobulinaemia: Report of 1235 Infusions
A total of 1235 immunoglobulin infusions were carried out as replacement therapy in 37 patients suffering from primary hypogammaglobulinemia from 1983 to 1987, using Scottish National Blood Transfusion Service (SNBTS) IV IgG, manufactured by cold ethanol fractionation of plasma, ultrafiltration and mild pepsin proteolysis at pH4. Ten patients experienced adverse reactions during 34 infusions (2.8% of all infusions) and all but five were mild; 21 (62%) of the adverse reactions were encountered in the patients' first five infusions. A maximum immunoglobulin infusion rate of 5 mg/kg/min was tolerated without adverse reaction.
JanewayCA. The development of clinical uses of immunoglobulins; a review. MerlerE, ed Immunoglobulins, biologic aspects and clinical uses. Washington: National Academy of Sciences1970; 3–14.
2.
BarandunSKistlerPJeunetFIslikerH.Intravenous administration of human gammaglobulin. Vox Sang1962; 7: 157–174.
3.
LeaverAMLWebsterADBBrownDThomasHC. Non-A non-B hepatitis and intravenous immunoglobulin. Lancet1984; ii: 1062–1064.
4.
OchsHDFischerSHVirantFSLeeMLKingdomHSWedgwoodRJ. Non-A non-B hepatitis and intravenous immunoglobulin. Lancet1985; i: 404–405.
5.
LeenCLSYapPLNeillGMcClellandDBLWestwoodA.Serum ALT levels in patients with primary hypogammaglobulinaemia receiving replacement therapy with intravenous immunoglobulin or fresh frozen plasma. Vox Sang1985; 50: 26–32.
6.
WelchAGMcIntoshRVFosterPR. Human immunoglobulin for clinical use. Lancet1983; i: 358.
7.
WicherJRPerryDEHobbsJR. An evaluation of the Hyland laser nephelometer PDQ for the measurement of immunoglobulin. Ann Clin Boichem1978; 15: 77–85.
8.
FischerH.Automatic registration of complement haemolysis and some applications. Int. Symposium on immunological methods of biological standardisation. Karger1967; 4: 221–228.
9.
LeenCLSYapPLMcClellandDBL. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualisation of intravenous immunoglobulin. Vox Sang1986; 51: 278–286.
10.
OchsHDFischerSHWedgwoodRJ. Modified immune globulin: Its uses in the prophylactic treatment of patients with immune deficiency. J Clin Immunol1982; 2: 22s–30s.
11.
OchsHDFischerSHWedgwoodRJComparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med1984; 76(3A): 78–82.
12.
EiblMMCairnsLRosenFS. Safety and efficacy of a monomeric, functionally intact intravenous IgG preparation in patients with primary immunodeficiency syndromes. Clin Immunol Immunopathol1984; 31: 151–160.
13.
AmmannAJAshmanRFBuckleyRHUse of intravenous gamma-globulin in antibody immunodeficiency: Results of a multicentre controlled trial. Clin Immuno Immunopathol1982; 22: 60–67.
14.
MatsumotoSKobayashiNGohyaN.Clinical trials of a suphonated immunoglobulin preparation for intravenous administration. II Adverse reactions. Eur J Pediatr1981; 136: 167–171.
15.
BarandunSMorellASkavrilF.Clinical experiences with immunoglobulin for intravenous use. In Immunoglobulins: characteristics and uses of intravenous preparations. Edited by AlvingBMFinlaysonJS. Food and Drug Administration, DHSS Publication No. (FDA)-80-9005, Washington DC1980; 31–35.
16.
Cunningham-RundlesCSmithwickEMSiegalFPTreatment of primary humoral immunodeficiency diseases with intravenous (pH4 treated) immunoglobulin. Immunohaemotherapy. A guide to prophylaxis and therapy. NydeggerUE (Ed). LondonAcademic Press1981; 283–290.
17.
PasswellJRosenFSMerlerE.The effect of Fc fragments of IgG on human mononuclear cell responses. In Immunoglobulins: characteristics and uses of intravenous preparations. Edited by AlvingBMFinlaysonJS. Food and Drug Administration, DHSS Publication No. (FDA)-80-9005, Washington DC1980; 139–142.
